medigraphic.com
ISSN 1729-6935 (Electronic)
16 de abril

2022, Number 283

<< Back Next >>

16 de abril 2022; 61 (283)

Long survival of a patient from Matanzas with lung cancer and brain metastasis. Case report

Sánchez-Lazo Y, Camacho-Sosa K, Martí-Coruña C

Language: Spanish
References: 12
Page: 1-5
PDF size: 549.18 Kb.


ABSTRACT

Lung cancer is the leading cause of death from malignant tumors and non-small cell lung cancer is the most frequent. It is characterized by a tendency to metastasize important organs such as the central nervous system, for which a mean survival of three to six months after treatment with radiation is estimated. We present the case of a 55 year old non-smoker patient, who was seen at the Oncology Department, where studies were performed, showing a nodular image in the lower lobe of the right lung; a sample was taken which reported squamous cell carcinoma, T2aN0M0 Stage Ib. Several treatment schemes were implemented, including surgical intervention. In November 2018, she passed away. This is a patient diagnosed with epidermoid carcinoma of the lung with brain and bone metastasis who achieved an overall survival of six years, exceeding the average established to date.


REFERENCES

  1. American Cancer Society [Internet].Washington: American CancerSociety; 2019 [updated 2021; cited04/26/2021]. Available from: http://www.cancer.org/cancer/acs-medical-content-and-staff.html

  2. Ministerio de Salud Pública. Direcciónde Registros Médicos y Estadísticasde Salud. Anuario Estadísticode Salud 2019. [Internet] La Habana;2020 [cited 04/21/2021]. Availablefrom: http://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%C3%B- 3nico-Espa%C3%B1ol-2019-ed-2020.pdf

  3. Camacho Sosa K, SantiestebanÁlvarez E, Herrera Suárez A, CarreñoRolando IE. Ensayos clínicos en pacientescon cáncer de pulmón en Matanzas.Rev. med. electronica [Internet].2019 [cited 04/21/2021]; 41(5):[aprox. 0 p.] Available from: http://revmedicaelectronica.sld.cu/index.php/rme/article/view/3383

  4. Reck M, Popat S, Reinmuth N et al.Metastatic non-small-cell lung cancer(NSCLC): ESMO Clinical PracticeGuidelines for diagnosis, treatmentand follow-up. Annals of Oncology[Internet]. 2014 [cited 04/26/2021];25(3):27-39. Available from: https://doi.org/10.1093/annonc/mdu199

  5. Jemal A, Siegel R, Xu J, Ward E.Cancer statistics. CA Cancer J Clin[Internet]. 2010 [cited 04/27/2021]; 60(5):277-300. Available from: http://onlinelibrary.wiley.com/doi/10.3322/caac.20073/

  6. Pallis AG, Syrigos K. Targeted(and chemotherapeutic) agents asmaintenance treatment in patientswith metastatic non-small-cell lungcancer: Current status and futurechallenges. Cancer Treat Reviews[Internet]. 2012 [cited 04/25/2021];38(7):861-867. Available from:https://pubmed.ncbi .nlm.nih.gov/22217701/

  7. American Cancer Society [Internet].Washigton: American Cancer Society;2019 [updated 2021; cited 04/26/2021].Tratamiento del cáncer de pulmón nomicrocítico. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/9439.00.pdf

  8. Barker AJ, Gibson KH, Grundy W,Godfrey AA, Barlow JJ, HealyMP, et al.Studies leading to the identificationof ZD1839 (IRESSA): an orally active,selective epidermal growth factor receptortyrosine kinase inhibitor targetedto the treatment of cancer. BioorgMed Chem Lett [Internet]. 2001 [cited04/21/2021]; 11(14):191-4. Availablefrom: https://pubmed.ncbi.nlm.nih.gov/11459659/

  9. Hua/qing W, Yangang R, Zheng/ziQ, Kai F, Hui/lai Z, Wei Li, et al. Nimotuzumabcombined with gemcitabineand cisplatin as second/line chemotherapyfor advanced non/small/celllung cancer. Thoracic Cancer [Internet].2012 [cited 04/27/2021]; 3(1):72-78. Available from: https://pubmed.ncbi.nlm.nih.gov/11459659/

  10. CECMED. [Internet] La Habana:CECMED; 2019 [cited 04/28/2021].Resumen de las característicasdel producto CIMAHER (Nimotuzumab).Available from https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cimaher.pdf

  11. González-Palomo A, Carr-Pérez A,León-Monzón K, Blanco R, López-MedinillaA. El receptor del factor de crecimientoepidérmico y el N-glicolil GM3y su contribución a la progresión tumoral.Bases para una inmunoterapiacombinada. Anales de la Academia deCiencias de Cuba [Internet]. 2019 [cited04/21/2021]; 9(3): [aprox. 716 p.]. Availablefrom: http://www.revistaccuba.sld.cu/index.php/revacc/article/view/716

  12. Hernández Casola T, Pérez MoralesY, Trujillo Tirado T. Elevada supervivenciaen paciente con cáncer depulmón avanzado tratada con Vaxira®. MediCiego [Internet]. 2020 [cited04/21/2021]; 26(1): [aprox. 0 p.]. Availablefrom: http://www.revmediciego.sld.cu/index.php/mediciego/article/view/1125




2020     |     www.medigraphic.com